| Literature DB >> 31569309 |
Mahbobeh Koohiyan1, Fatemeh Azadegan-Dehkordi2, Farideh Koohian3, Morteza Hashemzadeh-Chaleshtori2.
Abstract
Diagnosis of pre-lingual hearing loss (HL) is difficult owing to the high number of genes responsible. The most frequent cause of HL is DFNB1 due to mutations in the GJB2 gene. It represents up to 40% of HL cases in some populations. In Iran, it has previously been shown that DFNB1 accounts for 16-18% of cases but varies among different ethnic groups. Here, we reviewed results from our three previous publications and data from other published mutation reports to provide a comprehensive collection of data for GJB2 mutations and HL in northern Iran. In total, 903 unrelated families from six different provinces, viz., Gilan, Mazandaran, Golestan, Ghazvin, Semnan, and Tehran, were included and analyzed for the type and prevalence of GJB2 mutations. A total of 23 different genetic variants were detected from which 18 GJB2 mutations were identified. GJB2 mutations were 20.7% in the studied northern provinces, which was significantly higher than that reported in southern populations of Iran. Moreover, a gradient in the frequency of GJB2 mutations from north to south Iran was observed. c.35delG was the most common mutation, accounting for 58.4% of the cases studied. This study suggests that c.35delG mutation in GJB2 is the most important cause of HL in northern Iran.Entities:
Keywords: GJB2 insertion; Gap junction protein beta 2; Genetic counseling; Hearing loss
Year: 2019 PMID: 31569309 PMCID: PMC6773957 DOI: 10.7874/jao.2019.00059
Source DB: PubMed Journal: J Audiol Otol
Characteristics of included studies
| Number | First author | Year | Province | Detection method | Case | Hearing loss type | Reference |
|---|---|---|---|---|---|---|---|
| 1 | Chaleshtori | 2002 | Gilan | ARMS-PCR and sanger sequencing | 87 | ARNSHL | [ |
| 2 | Bazazzadegan | 2012 | Gilan | Sanger sequencing | 69 | NSHL | [ |
| 3 | Bazazzadegan | 2012 | Ghazvin | Sanger sequencing | 22 | NSHL | [ |
| 4 | Hosseinipour | 2005 | Golestan | ARMS-PCR and sanger sequencing | 55 | ARNSHL | [ |
| 5 | Bazazzadegan | 2012 | Golestan | Sanger sequencing | 30 | NSHL | [ |
| 6 | Bazazzadegan | 2012 | Tehran | Sanger sequencing | 173 | NSHL | [ |
| 7 | Chaleshtori | 2005 | Tehran | ARMS-PCR and sanger sequencing | 256 | ARNSHL | [ |
| 8 | Chaleshtori | 2007 | Semnan | Sanger sequencing | 111 | NSHL | [ |
| 9 | Bazazzadegan | 2012 | Mazandaran | Sanger sequencing | 100 | NSHL | [ |
ARMS-PCR: amplification-refractory mutation system PCR, ARNSHL: autosomal recessive non-syndromic hearing loss, NSHL: nonsyndromic hearing loss
The frequency of consanguinity among different provinces of north Iran
| Province | Gilan | Mazandaran | Golestan | Tehran | Semnan | Ghazvin |
|---|---|---|---|---|---|---|
| Consanguinity | 85 | 57 | 58 | 307 | 76 | 18 |
| Non-consanguinity | 71 | 43 | 27 | 122 | 35 | 4 |
| Total[ | 156 | 100 | 85 | 429 | 111 | 22 |
Total case number
Fig. 1.The prevalence of GJB2-related mutations in different regions of Iran (south 0-4% [27,44], northwest 22-27% [27,44], and central 13-15% [30,44]). Six north provinces (Gilan, Mazandaran, Golestan, Ghazvin, Semnan, and Tehran) are shown in the map.
GJB2 mutations, their frequencies and in silico analyses in six provinces of Iran
| Mutations | Gilan [ | Gilan [ | Mazandaran [ | Golestan [ | Golestan [ | Ghazvin [ | Tehran [ | Tehran [ | Semnan [ | Mutation type | Classification | Functional effect | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mutation taster | SIFT | ||||||||||||
| c.35delG | 39 (28.3) | 47 (27) | 47 (23.5) | 17 (28.3) | 10 (9.1) | 2 (4.5) | 48 (9.4) | 38 (10.1) | 14 (6.3) | Frameshift | T | Disease causing | NA |
| c.71G>A | - | - | 2 (1) | - | - | - | 2 (0.4) | 4 (1.16) | 5 (2.25) | Missense | T | Disease causing | Damaging |
| c.95G>A | - | - | 5 (2.5) | - | - | - | 2 (0.4) | 2 (0.58) | 1 (0.45) | Missense | NT | Disease causing | Damaging |
| c.136G>A | 2 (1.44) | - | - | - | - | - | - | - | - | Missense | NT | Disease causing | NA |
| c.139G>T | - | - | - | - | - | - | 1 (0.2) | - | - | Missense | NT | Disease causing | NA |
| c.167delT | - | - | - | - | 1 (0.9) | - | 1 (0.2) | - | - | Frameshift | T | Disease causing | NA |
| c.224G>A | - | - | 1 (0.5) | - | - | - | - | 1 (0.29) | - | Missense | NT | Disease causing | Damaging |
| c.229T>C | - | - | - | - | - | - | - | - | - | Missense | NT | Disease causing | Damaging |
| c.230G>A | - | - | 1 (0.5) | - | - | - | - | - | 2 (0.9) | Missense | NT | Disease causing | NA |
| c.235delC | 1 (0.72) | - | - | - | - | - | 6 (1.18) | - | - | Frameshift | T | Disease causing | NA |
| c.257C>A | - | - | - | - | - | - | 1 (0.2) | - | - | Missense | NT | Disease causing | NA |
| c.313-326del | - | - | - | - | - | - | - | 2 (0.58) | - | Frameshift | T | Disease causing | NA |
| c.326G>A | - | - | - | - | - | - | - | - | 1 (0.45) | Missense | NT | Disease causing | NA |
| c.327-328delGG | 1 (0.72) | 2 (1.15) | - | - | - | - | 1 (0.2) | - | - | Frameshift | T | Disease causing | NA |
| c.334-336delAA | - | - | - | - | - | - | - | 1 (0.29) | - | Frameshift | T | Disease causing | NA |
| c.358-360delGAG | - | - | 1 (0.5) | - | - | - | - | 7 (2.02) | - | Inframe deletion | NT | Disease causing | NA |
| c.427C>T | - | - | - | - | - | - | 3 (0.6) | 4 (1.16) | - | Missense | NT | Disease causing | Damaging |
| c.463-464delTA | - | - | - | - | - | - | - | 2 (0.58) | - | Frameshift | T | Disease causing | NA |
| c.487A>G | - | - | - | - | - | - | 2 (0.4) | - | - | Missense | NT | Disease causing | NA |
| c.511G>A | - | - | - | - | - | - | - | - | - | Missense | NT | Disease causing | Damaging |
| c.551G>C | 1 (0.72) | - | 1 (0.5) | - | - | 2 (4.5) | 4 (0.8) | 3 (0.87) | - | Missense | NT | Disease causing | Damaging |
| c.-23+1G>A | 2 (1.44) | - | 3 (1.5) | 1 (1.6) | - | - | - | 4 (1.16) | 1 (0.45) | Splice site | T | Disease causing | NA |
| c.79G>A | 1 (0.72) | 2 (1.15) | - | - | 2 (1.8) | - | - | 2 (0.58) | 2 (0.9) | Missense | NT | polymorphism | Tolerated |
| c.186C>T | - | - | - | - | - | - | - | - | - | Missense | NT | polymorphism | Benign |
| c.341A>G | - | 2 (1.15) | 1 (0.5) | - | 1 (0.9) | - | - | 1 (0.29) | 1 (0.45) | Missense | NT | polymorphism | Benign |
| c.380G>A | - | - | - | - | - | - | - | - | - | Missense | NT | polymorphism | Benign |
| c.457G>A | 3 (2.17) | 4 (2.3) | 5 (2.5) | 1 (1.6) | 2 (1.8) | - | 30 (5.9) | 4 (1.16) | 7 (3.15) | Missense | NT | polymorphism | Benign |
| c.478G>A | - | - | - | - | - | - | 1 (0.2) | 1 (0.29) | - | Missense | NT | polymorphism | Benign |
| c.608T>C | - | - | - | - | - | - | - | 1 (0.29) | - | Missense | NT | polymorphism | Benign |
| c.-3558C>T | - | - | - | - | - | - | 21 (4.1) | - | - | Missense | NT | polymorphism | Benign |
| Normal | 88 | 117 | 133 | 41 | 94 | 40 | 389 | 269 | 187 | - | - | - | - |
| Total | 138 | 174 | 200 | 60 | 110 | 44 | 512 | 346 | 222 | - | - | - | - |
Values are presented as n (%) unless otherwise indicated. SIFT: Sorting Intolerant from Tolerant, T: truncated protein, NA: not available, NT: non-truncated protein